Article and Video CATEGORIES

Cancer Journey

Search By

 Dr. Matthew Kurian completed a 6-year accelerated BS/MD program through Northeast Ohio Medical University and completed his internal medicine residency training at the University of Cincinnati Medical Center. He joined St. Elizabeth’s Cancer Center in Edgewood, Kentucky as a lung and breast cancer specialist. He has a passion for bringing academic level care into the community through the enrollment of patients in clinical trials and improving access, equity, and education for patients and medical trainees.

Program: Patient Education Ambassadors 2023-24
The 2023-2024 GRACE Patient Education Ambassadors discuss topics in a variety of cancers, from screening and treating prostate cancer to aiding in the cost of cancer treatment.
Author
Matthew Kurian, MD - Guest Faculty
Image
Patient Education Ambassadors 2023-24

Drs. Matthew Kurian, Karan Jatwani, and Karine Tawagi discuss risk factors for developing prostate cancer, PSA test in prostate cancer screening, biopsies in prostate cancer, among other relevant information about prostate cancer.

To watch the full playlist click here.

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.